Global Foam Concrete Market, 2022 - Latest Drivers,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
74
Global Foam Concrete Market, 2022 - Latest Drivers, Opportunities, Trends & Forecasts

Dublin, July 10, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Foam Concrete Market - Drivers, Opportunities, Trends & Forecasts up to 2022" report to their offering. The global foam concrete market is expected to grow at a CAGR of 4.4% during the forecast period 2016-2022 to reach $458.1 million by 2022

Residential segment is expected to maintain market dominance in application segments, driven by China and Japan. Asia Pacific and Middle East African countries are expected to contribute higher growth in global foam concrete market. Some of the key players in foam concrete are LafargeHolicim, CEMEX, CNBM, EUROCEMENT and VOTORANTIM Group, etc. Foam concrete is classified under lightweight aerated concrete, which is a slurry of cement with minimum 20% of foam entrained. Foam concrete is used in construction material due to the cheap price and suitable insulation property. Foam concrete helps to reduce weight and cost of constructiondue to a lighter density. Continuous economic development and improving our quality of life are the key parameters driving the lightweight concrete and foam concrete markets. Globally, the demand for foam concrete is growing consistently, especially in Asia Pacific and Europe. This growth is supported by increasing residential and construction industries in these regions. Currently, Asia Pacific is the global leader in the foam concrete market. China and India have built an advantage of having most of the manufacturing and infrastructure market, thus providing the maximum contribution in the regional and global foam concrete market. Europe is the second major consumer of global foam concrete market owing to high residential demand. APAC along with Middle East & African countries is expected to witness high growth rate during the forecast period due to growing industrialization. Chemical foaming agents are leading the market with better properties and cost effectiveness. Foam concrete based on protein/organic foaming agent, which contains animal by-products, is facing problems of shelf-life and odor. Some of the modern and recently developed technologies such as synthetic-enzyme based foaming agents have improved the stability of the foam concrete. Both synthetic foaming agent based foam concrete and protein foaming agent based foam concrete have a unique property, which makes them useful across their specific application areas. Synthetic foaming agent based foam concrete has low cost and high insulation properties, thereby leading the market. The study of the global foam concrete market provides the market size information and market trends along with the factors and parameters impacting it in both short and long term. The study ensures a 360° view, bringing out the complete key insights of the industry. These insights help the business decision makers to make better business plans and informed decisions for the future business. In addition, the study helps the venture capitalist in understanding the companies better and take informed decisions. Report Scope: Applications - Residential - Infrastructure - Industrial - Others (such as garden, pavements) Materials - Synthetic foaming agent - Protein foaming agent Regions - Asia Pacific - Europe - North America - Rest of the World For more information about this report visit https://www.researchandmarkets.com/research/f...lobal_foam

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Cement and Concrete , Composites

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Lumexa Imaging's Investor Conference Push: Any Real Substance?

Updated Category News Views 132

Lumexa Imaging just dropped a line on Feb 17, 2026, about their upcoming investor conference gigs. Sure, they're strutting into multiple events—Raymond James in Orlando, Leerink Partners in Miami, and Barclays back-to-back days after that. But here’s the kicker: are these talks really worth the buzz? In a space where outpatient imaging claims to be kingpin, you’ve...

Continue Reading
Current Landscape of US Stock Futures Amid Rate Cuts

Updated Category News Views 173

Insights on the Current Stability of U.S. Stock Futures During Asian trading hours, U.S. stock index futures have held steady. Investors are hoping for interest rate cuts as the Federal Reserve's next meeting approaches. This meeting is expected to reveal a significant easing cycle that many in the market are eagerly anticipating. Even with strong reports on consumer and...

Continue Reading
Wispr Flow Revolutionizes Voice Dictation Across Platforms

Updated Category News Views 469

Wispr Flow Expands Its Reach in Voice Dictation Technology In a world where speed and efficiency are paramount, Wispr, known as The Voice Interface Company, is revolutionizing the way we interact with technology. With the recent launch of Wispr Flow for Windows, this innovative voice productivity tool is now accessible to users across both Mac and Windows platforms,...

Continue Reading
MintMiner: Your Ultimate Gateway to Cloud Mining Success

Updated Category News Views 197

Unlocking the Future of Cloud Mining with MintMiner In today's uncertain financial landscape, MintMiner presents an innovative solution for anyone looking to tap into the world of digital assets. As global financial systems face challenges, MintMiner offers a unique platform that makes cloud mining accessible, straightforward, and profitable. Understanding Cloud Mining...

Continue Reading
GT Biopharma's Strategic Move: Withdrawal of S-1 Registration

Updated Category News Views 100

GT Biopharma's Strategic Withdrawal of Form S-1 Registration GT Biopharma, Inc. (NASDAQ: GTBP) recently made headlines with its request for withdrawal of a Form S-1 registration statement. This decision marks a crucial moment for the company, based in San Francisco, known for its innovative approach in the immuno-oncology sector. GT Biopharma focuses on the development of...

Continue Reading